AZUR-1 presented by
@AndreaCercek @MSKCancerCenter: dostarlimab x 6 months in locally advanced dMMR/MSI-H #
rectalcancer# (recently FDA approved): 71% clinical complete response (cCR) rate, 100% durable (2 cCR patients had surgery with path complete response (pCR)), overall 76% had cCR at 12 months or pCR #
ESMO26#
@myESMO #
crcsm#